Trial · NCT03616184
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
NCT03616184, Phase 2, Completed, University of Nebraska; results first posted 2023-08-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids. Trials, record NCT03616184. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03616184
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
- NCT number
- NCT03616184
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 49 participants, actual
- Lead sponsor
- University of Nebraska
- Conditions
- Graft-versus-host-disease (GVHD)
- Interventions
- Ruxolitinib
- First posted
- 2018-08-06
- Last updated
- 2023-10-05
- Results first posted
- 2023-08-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Complete and Partial Responses in Skin and/or Joint | 6 months | The primary endpoint of the study was complete or partial response in skin and/or joint defined according to the 2014 NIH cGVHD Consensus Criteria. Partial response for skin would be a decrease in NIH Skin Score by 1 or more points. Partial response in joint would be a decrease in NIH Joint and Fascia Score by 1 or more points or increase in P-ROM score by 1 point for any site. |
| Secondary | Percentage of Participants With Complete or Partial Responses Overall | 6 months | As determined by 2014 NIH Criteria which is a clinician overall severity score of 0 for complete response and clinician overall severity score decreased by 2 or more points on a 0-10 scale for partial response. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Complete and Partial Responses in Skin and/or Joint | 6 months | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants With Complete or Partial Responses Overall | 6 months | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Complete and Partial Responses in Skin and/or Joint | Ruxolitinib | 49 | percentage of participants | ||
| Percentage of Participants With Complete or Partial Responses Overall | Ruxolitinib | 47 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ruxolitinib | 47 | |
| Overall Study | COMPLETED | Ruxolitinib | 34 | |
| Overall Study | NOT COMPLETED | Ruxolitinib | 13 |
Source ClinicalTrials.gov
Adverse events34
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Ruxolitinib | 3 | 47 | 3 |
| other | Aspartate aminotransferase increased | Investigations | Ruxolitinib | 3 | 47 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Ruxolitinib | 5 | 47 | 8 |
| other | Dizziness | Nervous system disorders | Ruxolitinib | 3 | 47 | 3 |
| other | Dry Eye | Eye disorders | Ruxolitinib | 3 | 47 | 3 |
| other | Fatigue | General disorders | Ruxolitinib | 7 | 47 | 8 |
| other | Hypertension | Vascular disorders | Ruxolitinib | 4 | 47 | 4 |
| other | Insomnia | Psychiatric disorders | Ruxolitinib | 3 | 47 | 3 |
| other | Nausea | Gastrointestinal disorders | Ruxolitinib | 8 | 47 | 9 |
| other | Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders | Ruxolitinib | 3 | 47 | 3 |
1 to 10 of 34Source ClinicalTrials.gov
See all 34 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ruxolitinib | 4 | 47 |
| Total, other adverse events | Ruxolitinib | 29 | 47 |
| Total, serious adverse events | Ruxolitinib | 13 | 47 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39151112 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03616184
GET https://conductscience.org/api/trials/v1/NCT03616184/events?page=2